Although loss of IGFBP3 expression results in the reduction of tumor cell sensitivity to cisplatin in non-small cell lung cancers [34], we did not consistently observe similar effects of IGFBP3 on cisplatin resistance in OEC-M1 and TW2.6 cells (Figures S1B, D). Here, IGFBP3 is linked to neoplasm.